Mibefradil release expands calcium-channel-blocker choices.
D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D017277:Drug Approval; D006801:Humans; D020748:Mibefradil; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D001562:Benzimidazoles; D002121:Calcium Channel Blockers; D003692:Delayed-Action Preparations; D013764:Tetrahydronaphthalenes; D020748:Mibefradil